High-Quality Orforglipron CAS NO: 2212020-52-3 Quotes, Service
Product Description
Mechanism & Efficacy
Orforglipron is a novel GPR40 (FFAR1) agonist, designed to enhance insulin secretion in response to elevated glucose levels. By selectively activating GPR40 receptors in pancreatic β-cells, Orforglipron improves glucose-dependent insulin release, potentially offering benefits in type 2 diabetes management. Early clinical data suggest improvements in glycemic control, HbA1c reduction, and beta-cell function, making it a promising candidate for research and development.
Dosage & Clinical Use
In original research studies, Orforglipron has been administered as an oral tablet, with doses typically ranging from 10 mg to 50 mg per day, adjusted according to clinical trial protocols and patient response. Dosage may vary in experimental studies, and all applications should follow ethical and regulatory guidelines.
Patent & Intellectual Property
Orforglipron is subject to ongoing patent filings. A preparation method for the GLP‑1 receptor agonist Orforglipron has been published under Chinese patent application CN117964617A (filed December 29, 2023, pending). Additional intellectual property protections, including formulation, synthesis, and method‑of‑use patents, are under development and may be pursued globally as the program advances.
Quality & Compliance
Orforglipron is manufactured under strict cGMP conditions at ThinHeal’s Shaoxing facility, ensuring batch-to-batch consistency, high purity, and stability. Comprehensive quality testing is performed for identity, assay, pH, and solubility to guarantee research-grade standards.
Customer Service & Shipping
We provide technical support and guidance for research applications. Shipping is available worldwide with temperature-controlled packaging to ensure product integrity.
Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist developed for the treatment of type 2 diabetes and obesity, aiding in weight loss and blood sugar control.
As a novel GPR40 (FFAR1) agonist, it selectively activates GPR40 receptors in pancreatic β-cells to enhance glucose-dependent insulin secretion and improve beta-cell function.
In clinical research settings, Orforglipron is administered as an oral tablet in daily dosages typically ranging from 10 mg to 50 mg based on trial protocols.
It is manufactured under strict cGMP conditions at ThinHeal’s Shaoxing facility, undergoing extensive identity, assay, pH, and solubility testing to ensure research-grade purity.
Products are shipped globally utilizing temperature-controlled packaging to maintain high stability and product integrity during transportation.
